echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > JGH: Serum leucine-rich alpha2 glycoprotein may be a predictor of endoscopic remission in Crohn's disease

    JGH: Serum leucine-rich alpha2 glycoprotein may be a predictor of endoscopic remission in Crohn's disease

    • Last Update: 2022-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) in which intestinal damage accumulates


    Between October 2018 and July 2021, the researchers prospectively included CD patients treated with biologics


    The results showed that of the 53 patients who completed the 52-week observation, 20 (37.


    This study confirms that from the early stages of biological therapy, both FC and LRG have high


    Original source:

    Izuru Abe.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.